Given the labeling of multiple components of the EFR3-TTC7-FAM126-PI4KA complex by BirA-KRASG12V, the negative enrichment of EFR3A sgRNA in oncogenic KRAS-transformed cells, and the above correlation between increased EFR3A gene amplification and expression and pancreatic adenocarcinoma, we sought to experimentally test whether inhibiting EFR3A affects KRAS signaling and oncogenesis. The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.